Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mei Pharma Inc Cmn (MEIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 57,729
  • Shares Outstanding, K 36,770
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,860 K
  • 36-Month Beta 1.27
  • Price/Sales 3.15
  • Price/Cash Flow N/A
  • Price/Book 1.07

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.48 +6.08%
on 04/06/17
1.65 -4.85%
on 04/05/17
-0.01 (-0.63%)
since 03/21/17
3-Month
1.45 +8.28%
on 02/02/17
1.88 -16.49%
on 03/09/17
+0.03 (+1.95%)
since 01/20/17
52-Week
1.23 +27.64%
on 06/16/16
2.28 -31.14%
on 08/08/16
+0.05 (+3.29%)
since 04/21/16

Most Recent Stories

More News
MEI Pharma to Present at Needham Healthcare Conference

MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer,...

MEIP : 1.57 (-1.87%)
MEI Pharma to Present at Oppenheimer Healthcare Conference

MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer,...

MEIP : 1.57 (-1.87%)
Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for...

MEIP : 1.57 (-1.87%)
MEI Pharma to Host Annual Meeting of Stockholders

MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific time on Thursday,...

MEIP : 1.57 (-1.87%)
MEI Pharma Reports First Quarter Fiscal Year 2017 Results

MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its first quarter ended September 30, 2016. The Company...

MEIP : 1.57 (-1.87%)
MEI Pharma to Present at Stifel Healthcare Conference

MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer,...

MEIP : 1.57 (-1.87%)
Blog Coverage MEI Pharma and Helsinn Group Announced Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia

Upcoming AWS Coverage on Depomed Post-Earnings Results

MEIP : 1.57 (-1.87%)
DEPO : 11.37 (-2.99%)
Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting

LUGANO, Switzerland and SAN DIEGO, November 3, 2016 /PRNewswire/ --

MEIP : 1.57 (-1.87%)
Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for...

MEIP : 1.57 (-1.87%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Support & Resistance

2nd Resistance Point 1.66
1st Resistance Point 1.62
Last Price 1.57
1st Support Level 1.55
2nd Support Level 1.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.